Promising Dup15q drug trial halted early

NCT ID NCT05307679

Terminated Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called basmisanil in children aged 2 to 14 with Dup15q syndrome, a rare genetic condition that affects development. The goal was to see if the drug could improve daily living skills like communication and movement. The trial was stopped early after enrolling only 7 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUP15Q SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

15q11q13 microduplication syndrome hereditary mixed polyposis syndrome partial duplication of the long arm of chromosome 15

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DUP15Q SYNDROME

Contacts and locations

Show contact details

Locations

Children's Hospital Los Angeles

Los Angeles, California, 90010, United States
Evelina London Children's Hospital

London, SE1 7EH, United Kingdom
Hospital Sant Joan De Deu

Esplugues de Llobregas, Barcelona, 08950, Spain
Hospital Universitario La Paz

Madrid, 28046, Spain
Rush University Medical Center

Chicago, Illinois, 60612-3244, United States